SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

8 marketing jobs

SpringWorks Therapeutics logo
2 days ago

Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO)

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$151K/yr – $226K/yr
SpringWorks Therapeutics logo
2 weeks ago

Regional Marketing Lead - NF1-PN (Southeast)

SpringWorks Therapeutics

USA (Remote)Full time$184K/yr – $245K/yr
SpringWorks Therapeutics logo
2 weeks ago

Regional Marketing Lead - NF1-PN (Northeast)

SpringWorks Therapeutics

USA (Remote)Full time$184K/yr – $245K/yr
SpringWorks Therapeutics logo
6 weeks ago

Vice President, US Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$270K/yr – $371K/yr
SpringWorks Therapeutics logo
2 months ago

Executive Director, Brand Lead U.S. NF1-PN Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$243K/yr – $373K/yr
SpringWorks Therapeutics logo
3 months ago

Director, US HCP Marketing - Desmoid Tumor

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$165K/yr – $230K/yr
SpringWorks Therapeutics logo
5 months ago

Senior Manager, Congress Lead - U.S. Rare Tumors Marketing Operations

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$121K/yr – $182K/yr
SpringWorks Therapeutics logo
5 months ago

Vice President, U.S. Sarcoma Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)Full time$270K/yr – $371K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

8 jobs
SpringWorks Therapeutics logo

Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO)

SpringWorks Therapeutics

Boston, MA (Hybrid)

$151K/yr - $226K/yrIn-houseFull-timeSenior level7+ years exp.
2 days ago
SpringWorks Therapeutics logo

Regional Marketing Lead - NF1-PN (Southeast)

SpringWorks Therapeutics

USA (Remote)

$184K/yr - $245K/yrIn-houseFull-timeSenior level9+ years exp.
2 weeks ago
SpringWorks Therapeutics logo

Regional Marketing Lead - NF1-PN (Northeast)

SpringWorks Therapeutics

USA (Remote)

$184K/yr - $245K/yrIn-houseFull-timeSenior level9+ years exp.
2 weeks ago
SpringWorks Therapeutics logo

Vice President, US Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)

$270K/yr - $371K/yrIn-houseFull-timeDirector/executive10+ years exp.
6 weeks ago
SpringWorks Therapeutics logo

Executive Director, Brand Lead U.S. NF1-PN Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)

$243K/yr - $373K/yrIn-houseFull-timeSenior level12+ years exp.
2 months ago
SpringWorks Therapeutics logo

Director, US HCP Marketing - Desmoid Tumor

SpringWorks Therapeutics

Boston, MA (Hybrid)

$165K/yr - $230K/yrIn-houseFull-timeDirector/executive9+ years exp.
3 months ago
SpringWorks Therapeutics logo

Senior Manager, Congress Lead - U.S. Rare Tumors Marketing Operations

SpringWorks Therapeutics

Boston, MA (Hybrid)

$121K/yr - $182K/yrIn-houseFull-timeSenior level5+ years exp.
5 months ago
SpringWorks Therapeutics logo

Vice President, U.S. Sarcoma Marketing

SpringWorks Therapeutics

Boston, MA (Hybrid)

$270K/yr - $371K/yrIn-houseFull-timeDirector/executive10+ years exp.
5 months ago
SpringWorks Therapeutics logo
SpringWorks Therapeutics

Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO)

Boston, MA (Hybrid)

$151K/yr – $226K/yrSenior Level7+ years expFull time

Posted 2 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own and execute the market access strategy for OGSIVEO, guiding value proposition development, non-personal promotion, cross-functional pull-through, and payer/channel tactics across field execution.

  • Own value proposition and resources for payers and decision makers
  • Lead cross-functional strategy, content development, and measurement frameworks

Job Description

Responsibilities

  • Drive execution of the market access strategy for OGSIVEO, ensuring alignment between strategic priorities and field-facing tactics
  • Lead the development and evolution of the OGSIVEO value proposition and associated resources for payers, population-based decision makers, and channel customers
  • Head the strategy and execution of non-personal promotion initiatives for market access audiences, including cross-functional alignment, content development, channel optimization, and performance tracking
  • Help shape and drive pull-through of GPO strategy by aligning cross-functional partners around customer-facing tactics, field support needs, and execution priorities
  • Oversee cross-functional execution, including project management, issue identification and resolution, progression through internal review processes such as MLR, stakeholder training, and development of measurement frameworks to assess effectiveness
  • Conduct market research and access customer tactic creation in partnership with Brand team to communicate strategic imperatives and optimize value of SpringWorks products
  • Collaborate with Account Director Team and matrix partners to manage and execute payer and channel specific value propositions, strategies, and tactical plans to achieve business objectives and goals
  • Partners closely with Sales and Sales Advisory teams to translate value and access strategy into aligned, customer-facing execution and equip field teams with coordinated value messaging in a more competitive market
  • Monitor the evolving US market access environment, including payer trends, analytics, health policy developments, and customer or trade association activity, and translate implications into actionable recommendations
  • Other Duties & Responsibilities: - Support the pull-through of a value-focused pricing strategy while balancing financial impact with patient and customer experience - Collaborate cross-functionally to build strong partnerships and ensure timely capture of external customer insights that inform value, access, and pricing planning - Engage customers who influence product access and availability with a solution-oriented, innovative, and continuous-improvement mindset - Interface with external organizations (vendors, payers, PBMs, population-based decision makers, COA, NCODA, ASCO, NCCN, etc.)

Requirements

  • Bachelor's degree (business or related disciplines)
  • Advanced degree desirable (e.g., PharmD, MPH, MBA)
  • 7+ years of experience in pharma or biotech industry, including at least 3 years of internal market access or marketing experience
  • Expertise in the US market access environment (e.g., payers, health systems, pharmacies, health policy and reimbursement)
  • US market access oncology experience preferred
  • Strong understanding of US payer and channel dynamics, including how managed care organizations make decisions as well as a working knowledge of IDNs, distribution, specialty pharmacy, and GPOs
  • Experience with Commercial brand planning process and brand team engagement
  • Financial acumen, including resource allocation, budget management, and reporting
  • Oncology and/or rare disease experience
  • Ability to advance concepts, resources, and/or assets effectively through Medical, Legal, and Regulatory review

Preferred

  • Advanced degree desirable (e.g., PharmD, MPH, MBA)
  • US market access oncology experience preferred

Benefits

  • We offer best-in-class benefits for our team of SpringWorkers who work with urgency on behalf of patients suffering from devastating diseases. Interested in learning more, review additional information here Benefits .
SpringWorks Therapeutics logo

SpringWorks Therapeutics

4.2 Glassdoor

SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). At SpringWorks, we are committed to finding answers people with rare tumors need. We thrive in an atmosphere of passion and tenacity, fueled by the excitement of the possibilities science may unlock and driven to work with urgency because of the importance of our work. We value authenticity because diverse backgrounds, cultures, styles and abilities can only help us find the answers that people with rare tumors are looking for.

Founded in 2017
Stamford, Connecticut, USA
420 employees (27 in marketing)
www.springworkstx.com
73% recommend to a friend
84% CEO approval

Salaries

Posted range

$151K/yr – $226K/yr

Taken straight from the job posting.

See all SpringWorks Therapeutics salaries

Marketing Team

Marketing Team Size
25 (6% of company)
Median Career Experience
17.5 years
Median Tenure
2.5 years
Marketing Roles Posted (Last 30 Days)
3

People

Marketing Leadership

Elizabeth Dare
Elizabeth Dare
Rare Disease Oncology Associate Director, Thought Leader Liaison/Regional Marketing
At the company for 2 years 5 months
Maria Finlay
Maria Finlay
Executive Director Marketing
At the company for 2 years 6 months
Monica Stipanov
Monica Stipanov
Associate Director, Digital Marketing
At the company for 2 years 6 months
Laura Stamper Smith
Laura Stamper Smith
DIRECTOR, US MARKETING
At the company for 2 years 8 months

Funding

Total Funding
$1B
Last Raise
$275M
Post IPO Equity, 2 years ago

Funding History

  • Dec 2023
    Post IPO Equity • $275M
  • Sep 2022
    Post IPO Equity • $225M
  • Oct 2020
    Post IPO Equity • $287.5M

Traffic Signals

Monthly Visitors
11.9K
Traffic Source Mix
Search
49.8%
Direct
38%
Referral
6%
Social
4.8%
Paid
1.3%

Headcount Trend

Current headcount: ~421

Recent News

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Oct 21, 2025 • GlobeNewswire
SpringWorks Therapeutics Publishes Long-Term Efficacy and Safety Data for OGSIVEO® in Desmoid Tumors in Journal of Clinical Oncology
Oct 21, 2025 • Quiver Quantitative
SpringWorks Therapeutics Announces Publication of Long-Term
Oct 21, 2025 • GlobeNewswire
SpringWorks Therapeutics Announces Publication of Long-Term
Oct 21, 2025 • GlobeNewswire
Is SpringWorks Therapeutics Inc. stock bottoming out - Market Growth Review & Verified Technical Trade Signals
Oct 20, 2025 • newser.com
Risk Recap: Why SpringWorks Therapeutics Inc. stock could rally in 2025 - Short Setup & Risk Controlled Daily Plans
Oct 18, 2025 • nchmf.gov.vn
Risk Off: How SpringWorks Therapeutics Inc. stock valuations compare to rivals - July 2025 Setups & Safe Entry Point Alerts
Oct 18, 2025 • nchmf.gov.vn
How supply chain issues affect SpringWorks Therapeutics Inc. stock - Portfolio Performance Summary & Verified Momentum Stock Watchlist
Oct 18, 2025 • nchmf.gov.vn
How SpringWorks Therapeutics Inc. stock reacts to global recession fears - Weekly Trend Recap & Smart Investment Allocation Tips
Oct 17, 2025 • nchmf.gov.vn
Why SpringWorks Therapeutics Inc. stock could rally in 2025
Oct 17, 2025 • nchmf.gov.vn
Merck names new R&D chief for healthcare business
Sep 3, 2025 • pharmaphorum
Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug
Sep 2, 2025 • MedCity News
Merck’s SpringWorks Therapeutics gains European approval for Ogsiveo
Aug 20, 2025 • European Pharmaceutical Review
Merck unit gets first EU nod for a desmoid tumour treatment
Aug 19, 2025 • pharmaphorum
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Aug 19, 2025 • BioSpace
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Aug 18, 2025 • MarketScreener
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Aug 18, 2025 • SpringWorks Therapeutics, Inc.
EC approves Ogsiveo, first treatment for desmoid tumors
Aug 18, 2025 • Pharma Letter
SpringWorks Therapeutics announces EC approval for OGSIVEO
Aug 18, 2025 • thefly.com
Merck Secures Approval for Cancer Drug Following Billion-Euro Deal
Aug 18, 2025 • MarketScreener
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Aug 18, 2025 • SpringWorks Therapeutics, Inc.
Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Therapeutics Acquisition
Aug 11, 2025 • Bloomberg
M&A Trends in Pharma Report, Q2 2025 - Deals Fall to $32.9 Billion in Q2 2025, with Oncology Leading at 51 Transactions
Aug 8, 2025 • Research and Markets
Weak Dollar Causes Merck to Miss Expectations - New Forecast Announced
Aug 7, 2025 • MarketScreener
Merck KGaA raises forex-adj profit guidance on drugs, lab gear
Aug 7, 2025 • MarketScreener
Neurofibromatosis Type 1 Pipeline Market Insights Report 2025 | Analysis of 10+ Companies and 12+ Drugs
Jul 28, 2025 • Research and Markets
Plexiform Neurofibroma Treatment Report 2025 – For Strategy Officers And Market Intelligence Teams
Jul 24, 2025 • EIN Presswire
EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1
Jul 21, 2025 • PMLiVE
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Jul 21, 2025 • BioSpace
Merck's SpringWorks takeover delivers a drug approval
Jul 21, 2025 • pharmaphorum
Ezmekly becomes first approved EU therapy for NF1-PN in children and adults
Jul 21, 2025 • Pharma Times
EC grants conditional approval of Ezmekly in NF1
Jul 19, 2025 • Pharma Letter
SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
Jul 18, 2025 • Quiver Quantitative
Merck KGaA gets EU nod for SpringWorks' neurofibromas drug
Jul 18, 2025 • FirstWord Pharma
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Jul 18, 2025 • SpringWorks Therapeutics, Inc.
European Commission Grants Conditional Approval of Ezmekly® (Mirdametinib) for the Treatment of Adult and Pediatric Patients with Nf1-Pn
Jul 18, 2025 • MarketScreener
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Jul 18, 2025 • SpringWorks Therapeutics, Inc.
Merck KGaA Gets Conditional Approval To Market Ezmekly Drug in EU
Jul 18, 2025 • Morningstar.com
Merck KGaA Gets Conditional Approval To Market Ezmekly Drug in EU
Jul 18, 2025 • MarketScreener
CEO of Merck Welcomes SpringWorks Therapeutics Team in Stamford
Jul 11, 2025 • Oncodaily
Merck concludes SpringWorks acquisition for $3.4bn
Jul 2, 2025 • Yahoo Finance
Merck concludes SpringWorks acquisition for $3.4bn
Jul 2, 2025 • Pharmaceutical Technology
Merck KGaA completes acquisition of SpringWorks Therapeutics for $47 per share
Jul 1, 2025 • Investing.com
Merck KGaA Completes Acquisition of SpringWorks Therapeutics in $3.4 Billion Deal
Jul 1, 2025 • Pharmaceutical Executive
SpringWorks Therapeutics Completes Merger and Delisting
Jul 1, 2025 • TipRanks
German company completes acquisition of Stamford-based Springworks Therapeutics
Jul 1, 2025 • Hartford Business Journal
Merck KGaA, Darmstadt, Germany Acquires SpringWorks Therapeutics for $3.4M
Jul 1, 2025 • Contract Pharma
Merck Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
Jul 1, 2025 • Merck Group
SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs
Jun 26, 2025 • Bain Capital
Nirogacestat Receives Positive Opinion from CHMP in Desmoid Tumors
Jun 20, 2025 • CancerNetwork
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Jun 20, 2025 • SpringWorks Therapeutics, Inc.
Goldman, JPMorgan See Germany Leading Deals Revival in Europe
Jun 17, 2025 • Bloomberg
SpringWorks Therapeutics Announces Merger with Merck KGaA
Jun 16, 2025 • TipRanks
SpringWorks Merger Moves Forward with Regulatory Clearances
Jun 16, 2025 • Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 15, 2025 • Morningstar.com
HAPPY FATHER’S DAY and $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: OPOF, PRA, SWTX and FLS
Jun 15, 2025 • Morningstar.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 15, 2025 • GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 15, 2025 • Halper Sadeh LLC
HAPPY FATHER’S DAY and $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: OPOF, PRA, SWTX and FLS
Jun 15, 2025 • Monteverde & Associates PC
HAPPY FATHER’S DAY and $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: OPOF, PRA, SWTX and FLS
Jun 15, 2025 • GlobeNewswire
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition
Jun 14, 2025 • Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 9, 2025 • MarketScreener
$HAREHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of OPOF, PRA, SWTX and HURA to Take Action
Jun 9, 2025 • Morningstar.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 9, 2025 • PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Jun 9, 2025 • Morningstar.com
$HAREHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of OPOF, PRA, SWTX and HURA to Take Action
Jun 9, 2025 • Monteverde & Associates PC
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders
Jun 4, 2025 • Halper Sadeh LLC
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Jun 3, 2025 • MarketScreener
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Jun 3, 2025 • Morningstar.com
Neurofibromatosis Type 1 (NF1) Drug Development Gains Momentum Amid Growing Need for Safer, More Effective Therapies
Jun 3, 2025 • EIN Presswire
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Jun 3, 2025 • Business Wire
NCI Office of Cancer Survivorship Director Shares Poignant Message for Cancer Survivors Celebrating NCSD
May 29, 2025 • EIN Presswire
SpringWorks Therapeutics (SWTX) Surged on Acquisition News
May 27, 2025 • Yahoo Finance
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 27, 2025 • PharmiWeb
On the comeback trail, GSK's Blenrep scores thumbs up from Europe's CHMP
May 23, 2025 • FiercePharma
SpringWorks Therapeutics Inc. (SWTX) Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025 • StreetInsider.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025 • SpringWorks Therapeutics, Inc.
CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs
May 23, 2025 • Endpoints News
SpringWorks Therapeutics Inc. (SWTX) Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025 • StreetInsider.com
SpringWorks gets EU endorsement for genetic disorder treatment
May 23, 2025 • Seeking Alpha
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025 • Morningstar.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025 • MarketScreener
National Cancer Survivors Day: Celebrating Life, Raising Awareness, and Inspiring Hope for the Future
May 14, 2025 • EIN Presswire
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
May 9, 2025 • Nasdaq
All cash: Merck KGaA’s $3.9bn acquisition of SpringWorks
May 1, 2025 • BioXconomy
Merck KGaA to buy cancer specialist SpringWorks
May 1, 2025 • Chemistry World
Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint
Apr 29, 2025 • Genetic Engineering and Biotechnology News
Merck KGaA to Acquire SpringWorks Therapeutics
Apr 29, 2025 • Pharmaceutical Executive
Merck to acquire US-based biotech firm SpringWorks for $3.9bn
Apr 29, 2025 • World Pharmaceutical Frontiers
SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO
Apr 29, 2025 • Seeking Alpha
Merck KGaA Buying SpringWorks In $3.9 Billion Deal
Apr 28, 2025 • Pulse 2.0
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
Apr 28, 2025 • BioSpace
Merck KGaA strikes $3.9bn deal for SpringWorks
Apr 28, 2025 • Pharmaceutical Technology
Merck KGaA to buy cancer biotech SpringWorks for $3.9 billion
Apr 28, 2025 • Chemical & Engineering News
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
Apr 28, 2025 • Business Wire
Merck to Acquire US Biopharma Company SpringWorks Therapeutics
Apr 28, 2025 • CHEManager
Merck acquires SpringWorks Therapeutics in multibillion dollar deal
Apr 28, 2025 • The American Bazaar
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Apr 28, 2025 • Fierce Pharma
Watch Merck KGaA to Buy Springworks for $3.9B
Apr 28, 2025 • Bloomberg.com
Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition
Apr 28, 2025 • MedCity News

Links

www.springworkstx.comLinkedInX (Twitter)Crunchbase